Ann Arbor, MINCT03099356Now EnrollingIRB Ready

Metastatic Thyroid Cancer Clinical Trial in Ann Arbor, MI

Access cutting-edge metastatic thyroid cancer treatment through this phase 2 clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.

Sponsored by University of Michigan Rogel Cancer Center

Quick Self-Assessment

See if you qualify for this Ann Arbor location

Preparing your pre-screening questions…

Expert Care in Ann Arbor

Access metastatic thyroid cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic thyroid cancer treatment provided free

Apply for This Ann Arbor Location

Check if you qualify for this metastatic thyroid cancer clinical trial in Ann Arbor, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Ann Arbor

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Ann Arbor site if eligible
  4. 4Begin participation

About This Metastatic Thyroid Cancer Study in Ann Arbor

This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo imaging to evaluate efficacy once every 2 cycles.

Sponsor: University of Michigan Rogel Cancer Center

Who Can Participate

Inclusion Criteria

Histologically documented differentiated thyroid cancer with or without metastases, not amenable to curative treatment; or the patient has documented refusal of curative treatment
Measurable disease (\>10 mm) and have progression of disease based on RECIST criteria. Previously irradiated tumor lesions are not considered measurable unless they have progressed since radiation.
Previous failure of Iodine-131 (131I) therapy or not candidates to receive 131I as assessed by treating physician.
Age ≥ 18 years
ECOG (Eastern Cooperative Oncology Group) performance status 0-2
Life expectance of ≥ 12 weeks
131I therapy not allowed within 24 weeks before entry (4 weeks if negative post-treatment scan)
Adequate organ and marrow function
Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment
Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment
Willingness and ability to comply with scheduled visits, treatment plans, including willingness to take study medication, laboratory tests, and other study procedures

Exclusion Criteria

Inability to obtain Foundation One testing on archival tissue, or, lack of previous Next Generation Sequencing
Chemotherapy, tyrosine kinase inhibitor, or radiation therapy within 4 weeks
Prior experimental therapy within 4 weeks of planned start of this trial
131I therapy within 24 weeks before entry (4 weeks if negative post-treatment scan)
Previous treatment with an mTOR inhibitor
Patients who are currently receiving treatment with strong inhibitors or inducers of CYP3A4 or P-glycoprotein that cannot be discontinued at least one week prior to the start of treatment with Cyclophosphamide and Sirolimus
Impairment of GI (gastrointestinal) function or GI disease that may significantly alter the absorption of study medications (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection) including dependence on a G-Tube for administration of medications.
A serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatment
Patients with known sensitivities to either cyclophosphamide and/or sirolimus
Patients with known urinary outflow obstruction
Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol
Patients (male and female) having procreative potential who are not willing or not able to use adequate contraception or practicing abstinence
Women who are pregnant or breast-feeding
Patients residing in prison

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Ann Arbor?

Yes, this clinical trial (NCT03099356) has an active research site in Ann Arbor, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Thyroid Cancer Treatment Options in Ann Arbor, MI

If you're searching for metastatic thyroid cancer treatment options in Ann Arbor, MI, this clinical trial (NCT03099356) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Ann Arbor research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced metastatic thyroid cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic thyroid cancer clinical trials near you to find additional studies recruiting in your area.

More Thyroid Cancer Trials in Ann Arbor, MI

See all thyroid cancer clinical trials recruiting in Ann Arbor — not just this study.

Browse Thyroid Cancer Trials in Ann Arbor →

Browse More Trials by Condition

Thyroid Cancer TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsOsteogenesis Imperfecta TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Ann Arbor?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Ann Arbor, MI